AbCellera Biologics Inc.

NASDAQ•ABCL

CEO: Dr. Carl L.G. Hansen Ph.D.

セクター: Healthcare

業種: Biotechnology

上場日: 2020-12-11

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

連絡先情報

2215 Yukon Street, Vancouver, BC, V5Y 0A1, Canada

604-559-9005

www.abcellera.com

時価総額

$1.11B

PER (TTM)

-7.4

17.4

配当利回り

52週高値

$6.52

52週安値

$1.89

52週レンジ

38%

順位37Top 34.1%

4.4

F-Score

改良版 Piotroski 分析

7年ファンダメンタル

堅調 • 4.4 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2019-2025

財務ダッシュボード

Q4 2025 データ

売上高

$44.85M+0.00%

直近4四半期の推移

EPS

-$0.03+0.00%

直近4四半期の推移

フリーCF

-$44.59M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Significant Revenue Increase Total revenue reached $75.1M USD in 2025, marking a 161% increase from $28.8M USD in 2024.

Loss from Operations Reduced Loss from operations narrowed to ($217.1M) USD in 2025, improving from ($314.8M) USD last year.

Internal Pipeline Progressing Advanced two internal drug candidates into clinical trials; 19 total molecules now in the clinic.

Manufacturing Facility Operational Completed clinical manufacturing facility investment, shifting focus to pipeline development and value realization.

リスク要因

Incurred Losses Continue Incurred losses in 2025 ($146.4M USD net loss); profitability timing remains uncertain, requiring continued expenditures.

Drug Development Inherent Risk Drug candidates face inherent uncertainty; none may achieve marketing approval or become viable commercial drugs.

Reliance on Partner Success Future value heavily depends on partners successfully developing and commercializing discovered antibodies for royalties.

Cash Reserves Decreasing Total cash, equivalents, and securities decreased 14.7% to $533.8M USD by year-end 2025.

見通し

Internal Pipeline Investment Allocating substantial resources to internal pipeline development, expecting near-term losses before long-term revenue.

Key Data Readouts Expected Anticipate topline data for ABCL635 in Q3 2026 and ABCL575 in Q4 2026 from ongoing trials.

Leveraging Integrated Platform Utilizing completed integrated platform investments to drive first-in-class medicines against challenging targets.

Anticipated IND/CTA Submissions Plan to submit IND/CTA for next two internal programs, ABCL688 and ABCL386, during 2027.

同業比較

売上高 (TTM)

XERS

$291.85M

+43.7%

RCUS

$247.00M

-4.3%

SYRE

$90.49M

+0.0%

粗利益率 (最新四半期)

CLDX

100.0%

+0.0pp

ABCL

100.0%

+588.5pp

NUVB

99.0%

+182.9pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
CELC	$5.36B	-31.9	-179.0%	67.3%
EWTX	$3.32B	-19.0	-32.0%	0.7%
VERA	$3.00B	-9.0	-59.7%	10.5%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

119.6%

高成長

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年5月6日

EPS:-

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし